We invest in people.

In Life Sciences
& Chemistry.

Our
Track Record

Life Sciences and Chemistry

“HTGF is very supportive and easy to work with.
They foster a collaborative environment and respond very fast to any request.

David Neale

Founder and CEO of Argá Medtech

Spotlight
Life Sciences & Chemistry

8 of 500 Companies
2022

EEDEN

Recycling

From textile waste to tomorrow’s resources.

to EEDEN
2021

Argá Medtech

Life Sciences

Optimization of atrial fibrillation therapy via precise, non-thermal pulsed field ablation

to Argá Medtech
2020

Tubulis

Oncology

Development of enhanced antibody-drug conjugates for improved cancer treatment

to Tubulis
2019

Biograil

Drug Delivery

Breakthrough technology for the oral delivery of biologics in a standard size capsule

to Biograil
2019

Emergence Therapeutics

Exit
Oncology

Novel antibody drug conjugates to treat high need cancers

to Emergence Therapeutics
2017

CARDIOR

Exit
Cardiology / Cardiovascular

Pioneer in the development of new therapeutics for heart disease

to CARDIOR
2011

MYR

Exit
Pharmaceuticals

First-in-class Entry-Inhibitor for the treatment of chronic hepatitis Delta

to MYR
2006

c-LEcta

Exit
Industrial Biotech

c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …

to c-LEcta
3 of 500 Companies

Tomorrows market will be different
We invest now

Pharma, BioTech, R&D Tools and Diagnostics

Germany is one of the global leaders in life science research. We invest in disruptive technologies and visionaries not only to further innovation, but also to actively shape the market.

MedTech and Digital Health

Societal challenges such as demographic change, the shortage of skilled workers or complex diseases demand visionary answers. Together, we transform these into market-relevant solutions.

Chemistry

How do we feed a growing world population in the future, how do we counter the effects of climate change? We believe in the answers provided by science – and we know the challenges of lab-to-market startups from our own experience.

Success stories
People invest in People

Last update 7 days ago
zum Artikel

News

15. October 2025

HTGF Portfolio Company Tubulis Raises €308M in Record-Breaking Series C Financing

zum Artikel

News

7. July 2025

EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease.

zum Artikel

News

29. April 2025

eeden Closes €18M Series A Financing to Scale its Breakthrough Textile Recycling Technology

zum Artikel

News

15. April 2025

HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration

zum Artikel

News

7. April 2025

Successful exit for HTGF: German Medical Engineering joins the Thomas Group 

zum Artikel

News

29. October 2024

Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Science-driven with entrepreneurial spirit
The Life Sciences & Chemistry Team

Zum Artikel

Dr. Angelika Vlachou Partner

Dr. Angelika VlachouPartner

Zum Artikel

Dr. Bernd Goergen Partner

Dr. Bernd GoergenPartner

Zum Artikel

Marco Winzer Partner

Marco WinzerPartner

Zum Artikel

Dr. Anke Caßing Principal

Dr. Anke CaßingPrincipal

Zum Artikel

Dr. Caroline Fichtner Principal

Dr. Caroline FichtnerPrincipal

Zum Artikel

Kay G. Balster Principal

Kay G. BalsterPrincipal

Zum Artikel

Dr. Frank Hensel Principal

Dr. Frank HenselPrincipal

Zum Artikel

Dr. Nikolaus Raupp Principal

Dr. Nikolaus RauppPrincipal

Zum Artikel

Dr. Jörg Traub Principal

Dr. Jörg TraubPrincipal

Zum Artikel

Dr. Katharina Severin Senior Investment Manager

Dr. Katharina SeverinSenior Investment Manager

Zum Artikel

Dr. Jan Engels Senior Investment Manager

Dr. Jan EngelsSenior Investment Manager

Zum Artikel

Dr. Christian Kannemeier Senior Investment Manager

Dr. Christian KannemeierSenior Investment Manager

Zum Artikel

Dr. Lena-Sophie Schütter Investment Manager

Dr. Lena-Sophie SchütterInvestment Manager

Zum Artikel

Tilmann Petersen Investment Manager

Tilmann PetersenInvestment Manager

Zum Artikel

Dr. Stephan Ruck Investment Analyst

Dr. Stephan RuckInvestment Analyst

Zum Artikel

Calvin Kunth Junior Analyst

Calvin KunthJunior Analyst

Zum Artikel

David Düpjohann Junior Analyst

David DüpjohannJunior Analyst

Added Value.
The HTGF promise

We see the potential for real innovation before anyone else does – with a deep understanding of the market and excellent connections to research, institutes and universities. We are the door opener that your start-up needs in the financing round to revolutionise the market.

We invest
first.

open/close

Early-stage investments are at the heart of our business: we take early ristks on to ensure that your solution gets market ready.

Bridge-building: from science to venture.

open/close

As a diverse team drawn from science, medicine and entrepreneurs, we are familiar with the challenges you face – including those that await you tomorrow.

Our network is your superpower.

open/close

With our large network and over 45 companies invested in the fund, you will find the right partners to drive your business forward.

800 Ventures, one HTGF family.

open/close

Talents are your resource for success, collaborations your lever for transformation. Join the family – and grow beyond yourself.

Its you
who can change the world.

We have helped some of Germany’s most innovative companies get off the ground. We are the right partner for you, too, if…

  • you are R&D-based, but your business network needs to be expanded.
  • you have an innovative solution, technology or patent, but your lab-to-market strategy needs to be built.
  • your company is facing regulatory hurdles that overwhelm your team resources.
  • you are in an early phase and need a strong consortium for the challenging development.

Do you want to found in

Life Sciences or Chemistry?

Is your Pitch deck

ready to go?